CompletedNot Applicable

Systemic Immune-Inflamation Index and Mortality in ICU Patients

Turkey (Türkiye)570 participantsStarted 2025-12-01

Plain-language summary

Systemic Immune-Inflammation Index (SII) is a hemogram-derived biomarker reflecting the balance between systemic inflammation and immune response. In critically ill patients, inflammatory burden at admission may play a key role in prognosis. This retrospective cohort study aims to evaluate the association between admission SII levels and intensive care unit (ICU) mortality in adult patients admitted to a reanimation ICU. Secondary objectives include comparison of mortality according to infectious versus non-infectious admission diagnoses and assessment of the relationship between SII and established severity scores, including APACHE II and Glasgow Coma Scale (GCS). The findings may support the use of SII as a rapid, inexpensive prognostic marker in critically ill patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older * Admission to the reanimation intensive care unit * Availability of admission complete blood count and biochemical laboratory data * Admission due to infectious or non-infectious critical illness Exclusion Criteria: * Pregnancy * Hematologic malignancy * Active chemotherapy * Chronic immunosuppression * Pulse steroid therapy * Known thrombocytopenia (platelet count \<50×10\^9/L) * Massive bleeding or massive transfusion within the first 24 hours of ICU admission * Incomplete clinical or laboratory data

What they're measuring

ICU Mortality Rate

Timeframe: Duration of ICU stay (up to 90 days)

Trial details

NCT IDNCT07493759

SponsorAtaturk University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-18

View on ClinicalTrials.gov More Critical Illness trials